• Hebei Sinopack Electronic Technology

  Led · Equity · Nov 2023

  中瓷电子科技 is an electronic-ceramics series products manufacturer engaged in R&D, production and sales. Its main products include semiconductor heating elements and devices, microwave dielectric ceramics and devices, and automotive parts. Product lines cover microwave device packaging, high-density IC packaging, optoelectronic device packaging, MEMS packaging and automotive electronics. The company completed a directed issuance raising about RMB 2.5 billion to support production line construction and R&D investment. The placement involved issuance of 29,940,119 A-shares to seven specific investors, and the gross proceeds were approximately RMB 2.5 billion. After issuance-related fees of RMB 37.3094 million, the net proceeds amounted to RMB 2.463 billion.

• Xinmao New Energy

  Led · Series C · Oct 2023

  Shenzhen Xinmao New Energy Technology Co., Ltd., founded in 2015, focuses on research, manufacture and sales of lithium‑battery cathode and anode materials and new carbon materials. The company is a national high‑tech enterprise and is described as one of the earliest and largest Chinese firms repairing and recycling waste graphite and lithium‑iron phosphate (LFP) materials, and a setter of industry standards for anode-material recycling. Its cathode LFP and anode graphite recycling technologies have received national‑level appraisal and are said to reach international advanced levels. The company completed a C+ financing round of ¥100 million; the proceeds will be used to continue construction of a Guizhou production line, expand capacity and replenish working capital. Xinmao says it will also use the funds to further enhance talent competitiveness and product R&D capabilities. The article also notes broader industry progress in new carbon materials and potential expanded applications in electric vehicles, energy storage and other fields.

• Cygnus Biosciences

  Led · Series C · Aug 2022

  Saina Biotech, founded by a team including Peking University academician Xie Xiaoliang, Professor Huang Yanyi and Dr. Chen Zitian, is a high-tech company integrating gene-technology R&D, translation, production and sales. The company holds more than a hundred Chinese and PCT patents, with core patents authorized in the United States, and centers its technology on two proprietary sequencing innovations: Fluorogenic signal generation and error-correcting coding (ECC). It operates complete manufacturing and R&D capabilities including chemical and enzyme raw-material bases, a GMP reagent production workshop, an instrument factory, and optical, fluidics and algorithm teams. Based on this platform Saina launched the S100 sequencing system, a high-throughput, dual-mode, fast and accurate platform designed for flexible deployment and to meet domestic clinical needs for small samples, speed and low cost. In June 2022 the S100 instrument and companion reagent kits received EU CE-IVDR certification, clearing the way for sales in the European market. The company says it will continue next-generation sequencing R&D, accelerate S100 commercialization and build a China-led sequencing ecosystem to support national bioinformation security. SainaBio develops and industrializes high-throughput gene sequencing platforms, proprietary chips, and reagents aimed at clinical disease detection, diagnosis, and screening. Its core sequencing technologies—Fluorogenic emission and error-correcting ECC coding—were developed by teams led by prominent scientists including Prof. Xie Xiaoliang and Prof. Huang Yanyi. The company reports a multidisciplinary team of nearly 100 technical staff, with more than one-third of R&D personnel holding doctoral or master’s degrees and an instrument engineering team drawn from top domestic IVD firms. SainaBio has completed研发 and validation of its core technologies and produced a first-generation prototype that the company says matches or exceeds comparable international machines on cost, accuracy, and speed. The firm received a Beijing Municipal Science & Technology Commission project approval in September 2017. Proceeds from the recent financing will be used to finalize clinical registration, optimize and industrialize prototypes, scale instrument and chip production, and support product market entry.

No current team members are available.